$VOR News

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint

William Blair Initiates Coverage On Vor Biopharma with Outperform Rating

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks

Vor Biopharma: A Funded Replication Story With Franchise Potential

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Vor Bio To Participate in Upcoming September Conferences

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

UPDATE: Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate

Vor Bio Appoints David Zaccardelli to Board of Directors

Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next